P097 favorable safety profile for amiselimod, a selective s1p receptor modulator, in crohn ’s disease

Sphingosine 1-phosphate (S1P) receptor modulators are being developed to treat autoimmune-mediated diseases, including ulcerative colitis (UC) and Crohn ’s disease (CD). Amiselimod (AMS), a second-generation S1P receptor modulator, was developed to reduce bradycardia associated with other S1P receptor modulators, including fingolimod.

Source: Gastroenterology - January 25, 2020 Category: Gastroenterology Authors: Geert R.A.M. D ’Haens, Neal Slatkin, Robert Israel, Zeev Heimanson Tags: Adverse Events Related to Therapy Source Type: research